Allergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training
Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, today announced Allergan Medical Institute (AMI) will open three new ...
Scandal of the women harmed by medical implants who are BANNED from seeking compensation
Emma-Louise Lucas, a mother of one from Manchester, at just 31 received the shocking news that she had a rare type of cancer ...
MM&M1d
Rx Rundown: Novartis, Abcuro, SpringWorks Therapeutics and more
RxTechExam and the Pennsylvania Pharmacists Association announced a strategic partnership. Roche’s $8 billion InterMune acquisition has been handed to a specialty pharmaceutical company, Cayman ...
Science-Based Medicine1d
Botulinum Toxin: A tale of medicine, beauty, and danger
When used responsibly botulinum toxin is very safe, but patients should be especially vigilant about cosmetic treatments done ...
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...
BioSpace4d
AbbVie Gets FDA Approval for New Antibiotic in the Face of Rising Resistance
The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...
Le Lézard2d
CollPlant Biotechnologies Provides a Corporate Update
CollPlant Biotechnologies , or 'CollPlant', a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue ...
Poland Aesthetic Injectables Market to Reach Valuation of US$ 40.53 Million By 2033 | Astute Analytica
The future of Poland's aesthetic injectables market looks promising, with a projected increase in demand for hyaluronic acid ...
globes.co.il5d
Teva files to raise first capital since 2016
Teva has not raised capital since it acquired Actavis from Allergan in 2016 - a deal worth nearly $40 billion and for which ...
Implantable Drug Delivery Devices Market To Experience Steady Growth, Projected To Reach USD 57.1 Billion
The Global Implantable Drug Delivery Devices Market was valued at USD 26.7 Bn in 2023. It is expected to reach USD 57.1 Bn by 2033, with a CAGR of 8.1% ...